I have been having Reclast®/zoledronic acid infusions since 2009 (annually until 2012 and bi-annually since 2012 through October 2018). The last DXA scan in September 2018 showed there had been no significant interval change since the previous scan in 2016. However, the findings were:
- The lowest score was the Left femur (total) is osteoporotic (T-score of -2.7)
Would the new drug Romosozumab (Evenity®) be something to pursue? I am concerned about the FDA warning that it may increase the risk of heart attack, stroke or sudden death. Is it currently available?
You have Osteoporosis and are on treatment with an effective antiresorptive agent. If you have had a fracture, you should definitely consider an anabolic agent like Teriparatide (Forteo®) or Alabaratide (Tymlos®).
The newest option that has both bone building (anabolic) and antiresorptive effects is the monthly, injectable Evenity®/Rosomosumaub. This should be available by July 2019 by physicians specializing in Osteoporosis. Read our new column on Osteoporosis which will be published on May 1, 2019 and download our free treatment guidebook on Osteoporosis. Evenity® should not be initiated in someone who has had a heart attack or stroke in the last year.
All My Best,
Speaking of Women’s Health Nurse
April 23, 2019 at 4:40pm